Position of the Transparency Council – Voxzogo (vosoritide)
At its meeting on 18 November 2024, the Transparency Council adopted position No. 128/2024 on the evaluation of the drug Voxzogo (vosoritide) under the drug program “Treatment of patients with achondroplasia (ICD-10: Q77.4)”
Publication of the position >>